A Tefferi

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
    Ayalew Tefferi
    Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
    Blood 108:1497-503. 2006
  2. ncbi request reprint Is bone marrow biopsy essential for the diagnosis of essential thrombocythemia?
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Lymphoma 47:1724-5. 2006
  3. doi request reprint Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 36:1481-9. 2012
  4. doi request reprint Essential thrombocythemia treatment algorithm 2018.
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 8:2. 2018
  5. doi request reprint CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival.
    Natasha Szuber
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 8:21. 2018
  6. doi request reprint Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients.
    S Cerquozzi
    Division of Hematology, Department of Internal Medicine, University of Calgary, Calgary, AB, Canada
    Blood Cancer J 7:662. 2017
  7. doi request reprint Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?
    Maura Nicolosi
    Departments of Internal Medicine and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 8:8. 2018
  8. doi request reprint Anemia in myelofibrosis-prevalence, the U2AF1 connection, new treatments.
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA
    Blood Cancer J 7:648. 2017
  9. doi request reprint Chronic neutrophilic leukemia: new science and new diagnostic criteria.
    Natasha Szuber
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Blood Cancer J 8:19. 2018
  10. doi request reprint Momelotinib therapy for myelofibrosis: a 7-year follow-up.
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 8:29. 2018

Collaborators

Detail Information

Publications212 found, 100 shown here

  1. ncbi request reprint International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
    Ayalew Tefferi
    Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
    Blood 108:1497-503. 2006
    ..Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly...
  2. ncbi request reprint Is bone marrow biopsy essential for the diagnosis of essential thrombocythemia?
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Lymphoma 47:1724-5. 2006
  3. doi request reprint Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 36:1481-9. 2012
    ....
  4. doi request reprint Essential thrombocythemia treatment algorithm 2018.
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 8:2. 2018
    ..Herein, we provide a point-of-care treatment algorithm that is risk-adapted and based on evidence and decades of experience...
  5. doi request reprint CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival.
    Natasha Szuber
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 8:21. 2018
  6. doi request reprint Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients.
    S Cerquozzi
    Division of Hematology, Department of Internal Medicine, University of Calgary, Calgary, AB, Canada
    Blood Cancer J 7:662. 2017
    ..In conclusion, we identify distinct associations for arterial versus venous thrombosis in PV and confirm that a prior arterial or venous thrombotic event is the most reliable predictor of subsequent events...
  7. doi request reprint Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?
    Maura Nicolosi
    Departments of Internal Medicine and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 8:8. 2018
  8. doi request reprint Anemia in myelofibrosis-prevalence, the U2AF1 connection, new treatments.
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA
    Blood Cancer J 7:648. 2017
  9. doi request reprint Chronic neutrophilic leukemia: new science and new diagnostic criteria.
    Natasha Szuber
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Blood Cancer J 8:19. 2018
    ..Finally, we summarize and discuss current treatment options as well as prospective novel therapeutic targets in hopes that they will yield meaningful improvements in patient management and outcomes...
  10. doi request reprint Momelotinib therapy for myelofibrosis: a 7-year follow-up.
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 8:29. 2018
    ..9, 95% CI 1.9-32.1), and circulating blasts ≥2% (HR 3.9, 95% CI 1.4-11.0) predicted leukemic transformation. Post-MMB survival (median 3.2 years) was not significantly different than that of a risk-matched MF cohort not receiving MMB...
  11. doi request reprint Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q).
    Ayalew Tefferi
    Division of Hematology, Departments of Internal and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 7:658. 2017
  12. doi request reprint Myelodysplastic syndromes.
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 361:1872-85. 2009
  13. doi request reprint Polycythemia vera treatment algorithm 2018.
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 8:3. 2018
    ..In addition, it is reasonable to consider JAK2 inhibitor therapy, in the presence of protracted pruritus or markedly enlarged splenomegaly shown to be refractory to the aforementioned drugs...
  14. doi request reprint Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates.
    Sahrish Shah
    Division of Hematology, Department of Internal and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 7:657. 2017
  15. doi request reprint Genetic Risk Assessment in Myeloproliferative Neoplasms
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN Electronic address
    Mayo Clin Proc 92:1283-1290. 2017
    ..Further enhancement of genetic risk stratification in myeloproliferative neoplasms is possible by combining cytogenetic and mutation information and developing a prognostic model that is adjusted for age...
  16. ncbi request reprint Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Hematology Am Soc Hematol Educ Program . 2006
    ..Regardless, the discovery of JAK2V617F has reinforced the pathogenetic contribution of JAK-STAT signaling in MPD and identifies JAK2 as a valid drug target...
  17. doi request reprint Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN Electronic address
    Mayo Clin Proc 90:1283-93. 2015
    ..We do not use ruxolitinib in patients with PV unless they have severe pruritus or symptomatic splenomegaly that is proved to be refractory to hydroxyurea, interferon alfa, and busulfan...
  18. doi request reprint Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Nat Rev Clin Oncol 6:627-37. 2009
    ..We discuss histologic, cytogenetic and molecular changes in MPN and illustrate their integration into practical diagnostic algorithms...
  19. doi request reprint Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management
    Ayalew Tefferi
    Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 88:507-16. 2013
    ..Other disease features include leukocytosis, splenomegaly, thrombohemorrhagic complications, vasomotor disturbances, pruritus and a small risk of disease progression into acute myeloid leukemia or myelofibrosis...
  20. ncbi request reprint Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia
    A Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Br J Haematol 113:763-71. 2001
    ..Instead, +8, 12p-, advanced age and anaemia were independent prognostic determinants of inferior survival. In particular, survival was not adversely affected by the presence of either 20q- or 13q-...
  21. ncbi request reprint Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 106:1739-43. 2006
    ..For the current study, the authors explored the relation between specific cytogenetic clones and JAK2(V617F) mutational status in patients with MMM and the effects on treatment response to erythropoietin (Epo)...
  22. pmc Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Cell Mol Med 13:215-37. 2009
    ..The current review discusses the above listed mutant molecules in the context of their value as drug targets...
  23. doi request reprint A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2(V617F)
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Curr Hematol Malig Rep 1:81-6. 2006
    ..The results of these tests, along with the clinical scenario, determine the need for further investigation, including bone marrow examination...
  24. doi request reprint Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 86:1017-26. 2011
    ....
  25. ncbi request reprint Anemia in adults: a contemporary approach to diagnosis
    Ayalew Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:1274-80. 2003
    ..However, such classification is a starting point and not infallible. Each category then can be deciphered using a stepwise approach that utilizes readily accessible laboratory tests...
  26. ncbi request reprint Clinical, genetic, and therapeutic insights into systemic mast cell disease
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Curr Opin Hematol 11:58-64. 2004
    ..The purpose of this review is to summarize current concepts and recent advances in the pathogenesis and treatment of adult mast cell disease...
  27. ncbi request reprint Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 103:3547-8. 2004
    ..However, quantifying neutrophil PRV-1 mRNA, while complementary to other tests, is not in itself sufficient for the diagnosis of PV...
  28. ncbi request reprint Genomics basics: DNA structure, gene expression, cloning, genetic mapping, and molecular tests
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Cardiothorac Vasc Anesth 10:282-90. 2006
    ....
  29. ncbi request reprint Oncogenes in myeloproliferative disorders
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cell Cycle 6:550-66. 2007
    ..This increasing repertoire of mutant molecules has streamlined translational research and molecularly targeted drug development in MPDs...
  30. ncbi request reprint The history of myeloproliferative disorders: before and after Dameshek
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 22:3-13. 2008
    ..The current review considers these and other landmark events in the history of MPDs...
  31. doi request reprint Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota55905, USA
    Am J Hematol 83:491-7. 2008
    ..Herein, I will first outline my views regarding current management in ET, PV, and PMF and then discuss emerging data on preclinical and clinical activity of anti-JAK2 small molecule drugs. Am. J. Hematol., 2008. (c) 2008 Wiley-Liss, Inc...
  32. ncbi request reprint Idiopathic erythrocytosis: a non-entity?
    Ayalew Tefferi
    Department of Internal Medicine, Division of Hematology, Rochester, MN, USA
    Leuk Lymphoma 49:1649-50. 2008
  33. doi request reprint Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not
    Ayalew Tefferi
    Division of Hematology Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:265-7. 2009
    ..003). In PMF, the presence of a more severe erythropoietic defect, and not iron overload, has additional adverse prognostic value...
  34. pmc Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:158-64. 2010
    ..In the current review, we provide a simplified algorithm for distinguishing the various causes of clonal and idiopathic eosinophilia and discuss current therapy, including new drugs (imatinib mesylate, alemtuzumab, and mepolizumab)...
  35. doi request reprint How I treat myelofibrosis
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 117:3494-504. 2011
    ..I discuss these treatment approaches in the context of who should get what and when...
  36. doi request reprint Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients
    Ayalew Tefferi
    Divisions of Hematology, Mayo Clinic, Rochester, MN, USA
    Blood 118:4595-8. 2011
    ..2, 95% confidence interval 1.6-3.1; P < .01). The present information complements DIPSS-plus in the selection of primary myelofibrosis patients for high-risk treatment approaches...
  37. pmc One thousand patients with primary myelofibrosis: the mayo clinic experience
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 87:25-33. 2012
    ..To share our decades of experience with primary myelofibrosis and underscore the importance of outcomes research studies in designing clinical trials and interpreting their results...
  38. doi request reprint Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 88:141-50. 2013
    ....
  39. pmc Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
    Ayalew Tefferi
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 122:1395-8. 2013
    ..Additional criteria are provided for progressive disease, stable disease, and relapse. The document also includes recommendations for assessing cytogenetic and molecular remissions, without mandating their inclusion for CR assignment. ..
  40. pmc WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations
    M M Patnaik
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1283-9. 2010
    ....
  41. pmc Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
    D Caramazza
    Cattedra ed UO di Ematologia, Policlinico Universitario di Palermo, Palermo, Italy
    Leukemia 25:82-8. 2011
    ..5, 95% CI: 2.5-12.0; P<0.0001). This study provides the rationale and necessary details for incorporating cytogenetic findings and platelet count in future prognostic models for PMF...
  42. pmc Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    A Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:1322-7. 2013
    ..CYT387 is well tolerated and produces significant anemia, spleen and symptom responses in MF patients. Plasma cytokine and gene expression studies suggested a broad anticytokine drug effect...
  43. pmc Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium
    A Tefferi
    Division of Hematology, Department of Medicine, Rochester, MN, USA
    Blood Cancer J 1:e7. 2011
    ....
  44. doi request reprint SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML.
    R R Laborde
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:2100-2. 2013
  45. pmc Personalized management of essential thrombocythemia-application of recent evidence to clinical practice
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 27:1617-20. 2013
    ..In so doing, we are fully cognizant and sympathetic of the fact that some of our recommendations need to be tested in prospective controlled studies. ..
  46. pmc Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
    A Tefferi
    Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:1874-81. 2013
    ..Leukemic transformation was associated with treatment exposure to pipobroman or P32/chlorambucil. We found no association between leukemic transformation and hydroxyurea or busulfan use...
  47. doi request reprint JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:2721-30. 2012
    ....
  48. pmc IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:475-80. 2012
    ..Our observations suggest that IDH mutations in PMF are independent predictors of leukemic transformation and raise the possibility of leukemogenic collaboration with JAK2V617F...
  49. doi request reprint Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms
    Animesh Pardanani
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:1087-94. 2012
    ..Because of immediate practical applicability, we chose plasma immunoglobulin free light chain (FLC) concentration as the biomarker of interest...
  50. doi request reprint Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 87:285-93. 2012
    ..Other disease features include leukocytosis, splenomegaly, thrombohemorrhagic complications, vasomotor disturbances, pruritus, and a small risk of disease progression into acute myeloid leukemia or myelofibrosis...
  51. pmc If you feed them, they will come: a prospective study of the effects of complimentary food on attendance and physician attitudes at medical grand rounds at an academic medical center
    Colin M Segovis
    Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    BMC Med Educ 7:22. 2007
    ..The present study examined whether attendance at medical grand rounds increased after providing complimentary food to attendees and also assessed attendee attitudes about complimentary food...
  52. ncbi request reprint A long-term retrospective study of young women with essential thrombocythemia
    A Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 76:22-8. 2001
    ..To describe presenting clinical manifestations, long-term disease complications, prognostic indicators, and outcome of pregnancy for women younger than 50 years with essential thrombocythemia...
  53. ncbi request reprint Recent progress in the pathogenesis and management of essential thrombocythemia
    A Tefferi
    Mayo Clinic, Division of Hematology and Internal Medicine, 200 First Street SW, Rochester, MN 55095, USA
    Leuk Res 25:369-77. 2001
    ..Furthermore, randomized, prospective, and controlled retrospective data have provided additional clinical information that has resulted in the development of risk categories and risk-adjusted treatment recommendations...
  54. ncbi request reprint The pathogenesis of chronic myeloproliferative diseases
    A Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Int J Hematol 73:170-6. 2001
    ..This review discusses some of the current and past observations regarding the pathogenesis of chronic myeloproliferative disorders...
  55. ncbi request reprint Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literature
    S Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Hematol 80:430-5. 2001
    ..Here we describe a patient who developed pneumomediastinum, pneumopericardium, subcutaneous emphysema and pneumothorax secondary to severe bronchiolitis obliterans complicating the post bone marrow transplantation course...
  56. ncbi request reprint Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management
    A Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood Rev 15:121-31. 2001
    ..Clinicopathologic correlates to these biologic parameters are currently being defined...
  57. ncbi request reprint Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:3854-6. 2002
    ..In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit...
  58. ncbi request reprint Polycythemia vera: a comprehensive review and clinical recommendations
    Ayalew Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:174-94. 2003
    ....
  59. ncbi request reprint The forgotten myeloproliferative disorder: myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Oncologist 8:225-31. 2003
    ..New treatment approaches include the use of thalidomide alone or in combination with prednisone and hematopoietic stem cell transplantation...
  60. ncbi request reprint A contemporary approach to the diagnosis and management of polycythemia vera
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Rep 2:237-41. 2003
    ..This review outlines a practical approach to diagnosis, in addition to treatment of life-threatening and non-life-threatening complications of PV...
  61. ncbi request reprint Systemic mastocytosis: current concepts and treatment advances
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
    Curr Hematol Rep 3:197-202. 2004
    ..Cladribine has been shown to be effective in patients who develop resistance to interferon treatment...
  62. ncbi request reprint Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Int J Hematol 79:441-7. 2004
    ..The bone marrow histologic phenotype of these imatinib-sensitive eosinophilic disorders includes systemic mastocytosis, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, and atypical chronic myeloproliferative disorder...
  63. ncbi request reprint Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera
    Michelle A Elliott
    Mayo Clinic, 200 First Street SW, West 10 A, Division of Hematology, Rochester, MN 55905, USA E mail
    Curr Hematol Rep 3:344-51. 2004
    ..Additional patient management issues are raised during systemic anticoagulation and surgery. This review summarizes putative pathogenetic mechanisms of bleeding and their management in ET and PV...
  64. ncbi request reprint Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment
    Ayalew Tefferi
    Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 80:75-83. 2005
    ....
  65. ncbi request reprint The indolent natural history of essential thrombocythemia: a challenge to new drug development
    Ayalew Tefferi
    Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 80:97-8. 2005
  66. ncbi request reprint JAK2 in myeloproliferative disorders is not just another kinase
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cell Cycle 4:1053-6. 2005
    ..Taken together, these observations suggest that JAK2(V617F) is an acquired myeloid lineage-specific mutation that engenders a pathogenetic relevance for the PV phenotype in MPD...
  67. ncbi request reprint Modern diagnosis and treatment of primary eosinophilia
    A Tefferi
    Divisions of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Acta Haematol 114:52-60. 2005
    ..Allogeneic transplantation offers a viable treatment option for drug-refractory cases...
  68. ncbi request reprint Introduction to a cancer symposium for the practitioner
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1085-6. 2005
  69. ncbi request reprint Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 104:1656-60. 2005
    ..The current prospective study addresses this issue in the context of currently accepted independent prognostic variables...
  70. ncbi request reprint bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1220-32. 2005
    ..In this article, we outline contemporary diagnostic algorithms for each of these disorders and provide an evidence-based approach to management...
  71. ncbi request reprint Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia
    Ayalew Tefferi
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 131:166-71. 2005
    ..However, compared with the PRV-1 assay, mutation screening for JAK2(V617F) displayed greater accuracy in distinguishing PV from SP...
  72. ncbi request reprint Polycythemia vera: scientific advances and current practice
    Ayalew Tefferi
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Semin Hematol 42:206-20. 2005
    ..Despite recent progress in the field, several important issues remain controversial. In this review, we will present the areas of agreement, but also point out where the authors' personal viewpoints differ...
  73. ncbi request reprint Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates
    Ayalew Tefferi
    Division of Hematology, 200 First Street SW, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 30:677-80. 2006
    ..In the current study, we show that microcytosis is a frequent laboratory feature in agnogenic myeloid metaplasia and investigate its clinical relevance in the particular setting...
  74. ncbi request reprint Pathogenesis of myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 23:8520-30. 2005
    ..This latter phenomenon, through neutrophil-derived elastase, could also underlie the abnormal peripheral-blood egress of myeloid progenitors in MMM...
  75. ncbi request reprint The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
    Ayalew Tefferi
    Division of Hematology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, and Department of Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer 106:631-5. 2006
    ..Several studies have recently reported on the occurrence of a JAK2(V617F) mutation in myeloid cells from the majority of patients with polycythemia vera (PV). The clinical relevance of this novel observation currently is under study...
  76. ncbi request reprint New insights into the pathogenesis and drug treatment of myelofibrosis
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Curr Opin Hematol 13:87-92. 2006
    ..Advances have also been meager in terms of treatment for disease complications, including anemia, splenomegaly, and leukemic transformation...
  77. ncbi request reprint Essential thrombocythemia: scientific advances and current practice
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Curr Opin Hematol 13:93-8. 2006
    ....
  78. ncbi request reprint Mutation screening for JAK2V617F: when to order the test and how to interpret the results
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 30:739-44. 2006
    ..Therefore, mutation screening for JAK2V617F can be considered as a myeloid-specific clonality assay and it is diagnostically most useful in the evaluation of "polycythemia"...
  79. ncbi request reprint Iron chelation therapy for myelodysplastic syndrome: if and when
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:197-8. 2006
  80. ncbi request reprint Lenalidomide therapy in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 108:1158-64. 2006
    ..We conclude that lenalidomide engenders an intriguing treatment activity in a subset of patients with MMM that includes an unprecedented effect on peripheral blood and bone marrow abnormalities...
  81. ncbi request reprint Atypical myeloproliferative disorders: diagnosis and management
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 81:553-63. 2006
    ....
  82. ncbi request reprint Eosinophilia: secondary, clonal and idiopathic
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 133:468-92. 2006
    ..The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment...
  83. ncbi request reprint Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, Rochester 55905, USA
    Best Pract Res Clin Haematol 19:365-85. 2006
    ..Such progress is paving the way for a transition from a histologic to a semi-molecular classification system that preserves conventional terminology, while incorporating new information on molecular pathogenesis...
  84. ncbi request reprint The diagnosis of polycythemia vera: new tests and old dictums
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 19:455-69. 2006
    ..Recent discoveries of myeloproliferative-disease-specific molecular markers, including the JAK2 V617F tyrosine kinase mutation that is found in the majority of patients with PV, provide further support for such a measure...
  85. ncbi request reprint The diagnostic interface between histology and molecular tests in myeloproliferative disorders
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Curr Opin Hematol 14:115-22. 2007
    ..This review discusses how this process is unfolding in myeloproliferative disorders...
  86. ncbi request reprint Suppressors of cytokine signaling and regulation of clonal erythropoiesis
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leuk Lymphoma 48:7-8. 2007
  87. ncbi request reprint Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:2083-8. 2007
    ..Two other PSSs, Cervantes and Mayo, were recently reported as being more useful in younger patients. The current study compares these 3 PSSs among all age groups...
  88. ncbi request reprint Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests
    Ayalew Tefferi
    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 82:599-604. 2007
    ....
  89. ncbi request reprint Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Semin Thromb Hemost 33:313-20. 2007
    ..Whether the presence of this specific mutation or its allele burden modifies the risk of thrombosis in patients with MPDs currently is under investigation...
  90. ncbi request reprint Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms
    A Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 22:14-22. 2008
    ..The current review highlights these changes and also provides diagnostic algorithms that are tailored to routine clinical practice...
  91. ncbi request reprint JAK2 mutations and clinical practice in myeloproliferative neoplasms
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Cancer J 13:366-71. 2007
    ....
  92. doi request reprint Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 22:756-61. 2008
    ..We conclude that low V617F allele burden in PMF might indicate the presence of an overriding V617F-negative clone that confers a more aggressive disease phenotype...
  93. doi request reprint 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 80:386-90. 2008
    ....
  94. ncbi request reprint Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leuk Lymphoma 49:1225-7. 2008
  95. doi request reprint Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN, USA
    Leuk Res 33:662-4. 2009
    ..This preliminary report suggests a potential value for array CGH in terms of both clinical diagnostics and genomic research in MPNs...
  96. pmc Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
    A Tefferi
    Divisions of Hematology and Hematopathology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:900-4. 2009
    ..98). We conclude that TET2 mutations are frequent in SM, segregate with KITD816V and influence phenotype without necessarily altering prognosis...
  97. pmc TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:905-11. 2009
    ..05). We conclude that TET2 mutations occur in both JAK2V617F-positive and -negative MPN, are more prevalent in older patients, display similar frequencies across MPN subcategories and disease stages, and hold limited prognostic relevance...
  98. doi request reprint The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos
    Ayalew Tefferi
    Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 115:3842-7. 2009
    ..The revised WHO document continues to promote the recognition of histologic categories as a necessary first step toward the genetic characterization of myeloid malignancies...
  99. pmc Pomalidomide is active in the treatment of anemia associated with myelofibrosis
    Ayalew Tefferi
    Mayo Clinic, 200 First St SW, Rochester MN 55905, USA
    J Clin Oncol 27:4563-9. 2009
    ..However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the safety and therapeutic activity of another immunomodulatory drug, pomalidomide...
  100. doi request reprint JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leukemia 24:105-9. 2010
    ..Allelic distortion from acquired uniparental disomy contributes to the appearance of a more pronounced effect on disease susceptibility in VF-positive patients, when studying clonally affected tissue...